Trial
NCT05756907
Combination of SON-1010 (IL12-FHAB) and Atezolizumab in Patients With Platinum-resistant Ovarian Cancer
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Sonnet BioTherapeutics
Collaborators
Hoffmann-La Roche
Condition
Advanced Solid Tumor
Intervention
SON-1010
Why stopped
Failed to meet efficacy endpoint criteria, despite lack of safety concerns
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-03